We only have this paper's title and publication details.
Read it at the sourceSurging demand for modified immune cells causes some cancer trials to run short.
No takes yet. Share an insight, caveat, or question.
Jennifer Couzin-Frankel (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: